BioPharmSignal logoBioPharmSignal

Biotech News

ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences

ProQR Therapeutics (PRQR)ProQR TherapeuticsCompany update

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced upcoming presentations highlighting clinical and preclinical progress with AX-0810 and AX-0811 and the broader Axiomer RNA editing platform at TIDES Europe, The Liver Meeting 2026, Nature Conferences RNA at the Bench and Bedside V.

Related news

PRQRProQR Therapeutics2026-09-02 12:00 EST

ProQR to Participate in Upcoming Investor Conferences in September 2026

PRQRProQR Therapeutics2026-06-25 10:25 EST

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

SGHTSight Sciences2026-11-05 21:05 EST

Sight Sciences to Present at Two Upcoming Investor Conferences

OCGNOcugen2026-10-29 11:02 EST

Ocugen to Participate in Upcoming November Investor and Industry Conferences

OCGNOcugen2026-09-29 11:02 EST

Ocugen to Participate in Upcoming October Investor and Industry Conferences

OKYOOKYO Pharma2026-09-29 11:00 EST

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

EYPTEyePoint Pharmaceuticals2026-09-02 11:00 EST

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting

TARSTarsus Pharmaceuticals2026-11-05 21:30 EST

Tarsus to Participate in Upcoming Investor Conferences

BLTEBelite Bio2026-09-29 00:00 EST

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

BLTEBelite Bio2026-09-01 12:00 EST

Belite Bio to Participate in Four Upcoming Investor Conferences

View all latest news

ProQR Therapeutics

RNA Editing Company ProQR Therapeutics develops RNA-editing medicines using its Axiomer platform. Axiomer Technology Axiomer recruits endogenous ADAR enzymes to make precise single-base changes in RNA without permanently altering DNA. AX-0810 AX-0810 targets NTCP and is being developed initially for biliary atresia, with early clinical...

Recent company news

PRQRProQR Therapeutics2026-10-28 12:00 EST

ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences

PRQRProQR Therapeutics2026-09-23 12:00 EST

ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

PRQRProQR Therapeutics2026-09-09 12:00 EST

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

PRQRProQR Therapeutics2026-09-02 12:00 EST

ProQR to Participate in Upcoming Investor Conferences in September 2026

PRQRProQR Therapeutics2026-08-13 11:00 EST

ProQR Announces Second Quarter 2026 Operating and Financial Results

Stock data

Close
1.33 USD
Market cap
154.88M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States